News | July 26, 2024
Laurus Labs posts Q1 FY25 consolidated PAT at Rs. 12.51 Cr
Laurus Labs has reported total income of Rs. 1,197.42 crores during the period ended June 30, 2024
Laurus Labs has reported total income of Rs. 1,197.42 crores during the period ended June 30, 2024
The partnership will focus on creating capabilities for quickly and accurately processing vast amounts of clinical data
The discussion at the fourth session was centered on the fusion of academic rigor and industrial pragmatism as a key to pioneering solutions for sustainable and prosperous future
The product is bioequivalent and therapeutically equivalent to the reference listed drug
Shilpa Biologicals has developed high concentration adalimumab (100 mg/mL)
The drug will be manufactured at the group's formulation manufacturing facility in Ahmedabad SEZ - II, India
Thyrocare Technologies has reported total income of Rs. 160.53 crores during the period ended June 30, 2024
Torrent Pharmaceuticals has reported total income of Rs. 2,883 crores during the period ended June 30, 2024
Reported profit after tax declined 19% year-on-year to Rs 76 crores
The inspections concluded with no Form 483 observations or significant critical findings
Subscribe To Our Newsletter & Stay Updated
